Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 3 institutions in 1 country.
Eun-Sil LeeInnovative Drug-Like Library Research Center, Dongguk University, Pil-dong 3-ga, Jung-gu, Seoul 100-715, Korea.
Nayeon KimInnovative Drug-Like Library Research Center, Dongguk University, Pil-dong 3-ga, Jung-gu, Seoul 100-715, Korea.
Joon Hee KangDivision of Cancer Biology, National Cancer Center, Research Institute, Goyang 410-769, Korea.
Aizhan AbdildinovaInnovative Drug-Like Library Research Center, Dongguk University, Pil-dong 3-ga, Jung-gu, Seoul 100-715, Korea.ORCID 0000-0002-3577-0270
Seon-Hyeong LeeDivision of Cancer Biology, National Cancer Center, Research Institute, Goyang 410-769, Korea.ORCID 0000-0001-6492-1499
Myung Hwi LeeGraduate School of New Drug Discovery and Development, Chungnam National University, Daehak-ro 99, Yuseong-gu, Daejeon 305-764, Korea.
Nam Sook KangGraduate School of New Drug Discovery and Development, Chungnam National University, Daehak-ro 99, Yuseong-gu, Daejeon 305-764, Korea.
Tae-Sung KooGraduate School of New Drug Discovery and Development, Chungnam National University, Daehak-ro 99, Yuseong-gu, Daejeon 305-764, Korea.ORCID 0000-0001-8046-6836
Soo-Youl KimDivision of Cancer Biology, National Cancer Center, Research Institute, Goyang 410-769, Korea.
Young-Dae GongInnovative Drug-Like Library Research Center, Dongguk University, Pil-dong 3-ga, Jung-gu, Seoul 100-715, Korea.ORCID 0000-0002-7963-7789
Dongguk University · KRChungnam National University · KRNational Cancer Center · KR
Funding
National Research Foundation of Korea 2021R1F1A1058004
6 · The paper itself
Abstract
Cancer cells are characterized by an abnormal cell cycle. Therefore, the cell cycle has been a potential target for cancer therapeutic agents. We developed a new lead compound,
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Design and Synthesis of a Novel 4-aryl-N-(2-alkoxythieno [2,3- · full record | OpenQuestion